Automation Software Maker UiPath Rises in Market Debut 
 

The company's initial public offering raised about $1.3 billion, with trading in its shares valuing the business at more than $35 billion.

 
Hertz Proposes Shareholder Payout as Part of Bankruptcy-Exit Plan 
 

Hertz Global Holdings said an improved bankruptcy plan would provide some value to equity holders, vindicating the individual traders who have insisted the company is worth something despite its bankruptcy filing.

 
Pfizer Identifies Fake Covid Shots Abroad as Criminals Exploit Vaccine Demand 
 

In Mexico, about 80 people received fraudulent doses, and in Poland authorities recovered vials containing anti-wrinkle drugs.

 
FDA Finds Poor Conditions at Contractor's Plant Making J&J Vaccine 
 

Inspectors found that the Emergent BioSolutions plant that was helping make Johnson & Johnson's Covid-19 shot didn't maintain clean and sanitary conditions and didn't follow procedures to prevent contamination.

 
European, U.K. Company Earnings Previews 
 

Read what analysts are saying ahead of earnings due Thursday from Pernod Ricard, Informa, Rentokil and more.

 
Europe's Most Valuable Tech Company Can Help the Chip Shortage 
 

ASML is an expensive stock, but but it is in part an expression of the confidence in the company's ability to help fix the great chip shortage.

 
Verizon earnings and revenue rise, top expectations 
 

Verizon Communications Inc. topped earnings and revenue expectations Wednesday while detailing how its recent commitments for wireless spectrum will impact its financials.

 
Researchers Uncover Advertising Scam Targeting Streaming-TV Apps 
 

Fraudsters infected nearly one million mobile devices with software that mimicked streaming-TV apps and collected revenue from unsuspecting advertisers, according to a cybersecurity company.

 
Fatal Crash Has Negative ESG Implications for Tesla - ESG Insight 
 

The latest incident puts the electric-vehicle maker's Autopilot feature and its product quality and safety in the spotlight.

 
Biotech Stocks Fall Out of Favor After Disappointing Trial Results, Big Rally 
 

Biotech shares have plummeted over the past two months, stung by setbacks in clinical trials and a rotation away from growth stocks.

(END) Dow Jones Newswires

April 21, 2021 15:15 ET (19:15 GMT)